Mirodenafil prevents bladder dysfunction induced by chronic bladder ischemia in rats.

Area of Science:

• Urology
• Pharmacology
• Cardiovascular Research

Background:

• Chronic bladder ischemia (CBI) is a condition that can lead to significant bladder dysfunction.
• Understanding the underlying mechanisms and potential therapeutic interventions for CBI is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the protective effect of mirodenafil on bladder function in a rat model of chronic bladder ischemia (CBI).

Main Methods:

• Twenty-four Sprague-Dawley rats were divided into control, CBI, and CBI+mirodenafil groups.
• The CBI model involved endothelial injury and a high-cholesterol diet.
• Functional bladder studies (cystometry, detrusor muscle contractility) and histological analysis were performed.

Main Results:

• CBI rats exhibited increased micturition frequency, reduced bladder capacity, and lower compliance compared to controls.
• Mirodenafil treatment in CBI rats improved bladder capacity and compliance and reversed carbachol-induced contractile dysfunction.
• Histological analysis showed that mirodenafil reversed submucosal fibrosis and degenerative changes in bladder walls caused by CBI.

Conclusions:

• Mirodenafil demonstrated protective effects against bladder dysfunction induced by chronic bladder ischemia in a rat model.
• These findings suggest that mirodenafil may be a potential therapeutic agent for managing bladder dysfunction associated with CBI.